These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8103818)
61. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Sadowski M; Pankiewicz J; Scholtzova H; Ripellino JA; Li Y; Schmidt SD; Mathews PM; Fryer JD; Holtzman DM; Sigurdsson EM; Wisniewski T Am J Pathol; 2004 Sep; 165(3):937-48. PubMed ID: 15331417 [TBL] [Abstract][Full Text] [Related]
62. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842 [TBL] [Abstract][Full Text] [Related]
63. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view. Bird TD Ann Neurol; 1995 Jul; 38(1):2-4. PubMed ID: 7611719 [No Abstract] [Full Text] [Related]
72. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. Roses AD Neurobiol Aging; 1994; 15 Suppl 2():S165-7. PubMed ID: 7700444 [No Abstract] [Full Text] [Related]
73. Contemporary approaches to Alzheimer's disease and frontotemporal dementia. Roberson ED Methods Mol Biol; 2011; 670():1-9. PubMed ID: 20967579 [TBL] [Abstract][Full Text] [Related]
74. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Roses AD; Strittmatter WJ; Pericak-Vance MA; Corder EH; Saunders AM; Schmechel DE Lancet; 1994 Jun; 343(8912):1564-5. PubMed ID: 7911881 [No Abstract] [Full Text] [Related]
75. Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles. Pomara N; Nolan K; Halpern G Neurochem Res; 1995 Dec; 20(12):1519-20. PubMed ID: 8789616 [No Abstract] [Full Text] [Related]
76. The amplifying effect of beta-amyloid on cellular calcium signalling is reduced in Alzheimer's disease. Eckert A; Förstl H; Hartmann H; Czech C; Mönning U; Beyreuther K; Müller WE Neuroreport; 1995 May; 6(8):1199-202. PubMed ID: 7662907 [TBL] [Abstract][Full Text] [Related]
77. How autism and Alzheimer's disease are TrAPPed. Lahiri DK; Maloney B; Wang R; Sokol DK; Rogers JT; Westmark CJ Mol Psychiatry; 2021 Jan; 26(1):26-29. PubMed ID: 33184495 [No Abstract] [Full Text] [Related]